YAP1 and non-small cell lung carcinoma: The latter finding was somewhat unexpected because, at least in NSCLC, YAP/TEAD transcription factors have been shown to promote resistance to RAF- and MEK-targeted therapies via transcriptional upregulation of anti-apoptotic BCL2L1 (BCL2-like 1 or BCL-xL).